Evidence map›Paper›PMID 35877588›Full record

ReviewJournal of cardiovascular development and disease2022

Cardiotoxicity of Chemical Substances: An Emerging Hazard Class.

Nikolaos Georgiadis, Konstantinos Tsarouhas, Jean-Lou C M Dorne, George E N Kass, Petroula Laspa, Konstantinos Toutouzas, Elisabeth A Koulaouzidou, Dimitrios Kouretas, Christina Tsitsimpikou

Open access · goldAbstract readReview
In one paragraph

Review in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cardiovascular Toxicity Related to Cancer Treatment.Journal of cardiovascular development and disease · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Nikolaos GeorgiadisEuropean Chemicals Agency, 00150 Helsinki, Finland.
Konstantinos TsarouhasDepartment of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0003-2651-3579
Jean-Lou C M DorneEuropean Food Safety Authority, 43126 Parma, Italy.
George E N KassEuropean Food Safety Authority, 43126 Parma, Italy.ORCID 0000-0002-3343-5276
Petroula LaspaDepartment of Biochemistry & Biotechnology, University of Thessaly, 38221 Larissa, Greece.
Konstantinos ToutouzasFirst Department of Cardiology, Hippokration Hospital, Medical School, University of Athens, 11527 Athens, Greece.
Elisabeth A KoulaouzidouDivision of Dental Tissues' Pathology and Therapeutics (Basic Dental Sciences, Endodontology and Operative Dentistry), School of Dentistry, Aristotle University Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0002-3018-220X
Dimitrios KouretasDepartment of Biochemistry & Biotechnology, University of Thessaly, 38221 Larissa, Greece.ORCID 0000-0002-7469-6640
Christina TsitsimpikouDepartment of Biochemistry & Biotechnology, University of Thessaly, 38221 Larissa, Greece.
University of Thessaly · GREuropean Food Safety Authority · ITAristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Human health risks and hazards from chemical substances are well regulated internationally. However, cardiotoxicity, is not defined as a stand-alone hazard and therefore there are no defined criteria for the classification of substances as cardiotoxic. Identifying and regulating substances that cause cardiovascular adverse effects would undoubtedly strengthen the national health systems. (2) Methods: To overcome the aforementioned gap, a roadmap is proposed for identifying regulatory criteria from animal studies and endorse legislation in order to classify substances as cardiotoxic. The roadmap consists of: (i) the identification of the appropriate animal species and strains; (ii) the identification of the lines of scientific evidence (e.g., histopathological, biochemical and echocardiographic indices etc.) from animal studies with relevance to humans; (iii) the statistical analysis and meta-analysis for each line of scientific evidence after exposure to well-established cardiotoxicants to humans (e.g., anthracyclines) in order to identify threshold values or range of normal and/ or altered values due to exposure; (iv) validation of the above described lines of evidence in animals exposed to other alleged cardiotoxic substances (e.g., anabolic androgen steroids (AAS) and pesticides); (v) establishment of mechanisms of action based on information of either known or alleged cardiotoxicants; and (vi) introduction of novel indices and in silico methods. (3) Results: Preliminary results in rats indicate a clear distinction from normal values to values measured in rats exposed to anthracyclines regarding left ventricle (LV) fractional shortening (FS) and LV ejection fraction (EF). A distinctive pattern is similarly observed for Creatine Kinase-Myocardial Band isoenzyme (CK-MB) and cardiac tissue glutathione (GSH). These findings are encouraging and indicate that there is room for targeted research to this end, and that these specific indices and biochemical markers should be further investigated in order to be developed to regulatory criteria. (4) Conclusions: Further research should be conducted by both the scientific and regulatory community that aims to clearly define the cardiotoxicity hazard caused by chemicals and develop a full set of scientific criteria.

Indexed as

anthracyclinesbiochemical indicescreatine kinase-myocardial band isoenzymeechocardiographyejection fractionfractional shorteningglutathione peroxidaserats

Identifiers

PMID35877588
PMCPMC9316944
OpenAlexW4285595583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.